Cellectar Biosciences
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell CLRB and other ETFs, options, and stocks.About CLRB
Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124, which could detect tumors and metastases in a broad range of cancers, and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination.
CLRB Key Statistics
Stock Snapshot
With a market cap of 12.72M, Cellectar Biosciences(CLRB) trades at $3.00. The stock has a price-to-earnings ratio of -0.29.
On 2026-04-15, Cellectar Biosciences(CLRB) stock moved within a range of $2.96 to $3.06. With shares now at $3.00, the stock is trading +1.4% above its intraday low and -2.0% below the session's peak.
Trading activity shows a volume of 24.44K, compared to an average daily volume of 37.5K.
The stock's 52-week range extends from a low of $2.43 to a high of $20.59.
The stock's 52-week range extends from a low of $2.43 to a high of $20.59.
CLRB News
Cellectar Biosciences, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy...
Cellectar Biosciences (CLRB) announced that the first patient has been enrolled in the Phase 1b trial of CLR 121125 for the potential treatment of triple negati...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.